Dechao Jiao1, Yuan Yao1,2, Kaihao Xu1, Qinyu Lei1, Zongming Li1, Xinwei Han3,4, Jianzhuang Ren5. 1. Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 1 Jianshe Road, Zhengzhou, 450052, Henan, People's Republic of China. 2. Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China. 3. Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 1 Jianshe Road, Zhengzhou, 450052, Henan, People's Republic of China. 13592583911@163.com. 4. Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China. 13592583911@163.com. 5. Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 1 Jianshe Road, Zhengzhou, 450052, Henan, People's Republic of China. rjzjrk@126.com.
Abstract
PURPOSE: To evaluate the safety and feasibility of a newly designed 125I brachytherapy ureteral stent (BUS) in normal dogs. METHODS: A BUS loaded with 10 125I seeds (Group A: 0.8 mCi, Group B: 0.4 mCi, Group C: 0 mCi) was designed and tested in 27 normal beagle dogs. Routine blood tests, gross observations, cumulative radiation doses, tissue reaction assessed by hematoxylin-eosin/Masson staining, mRNA analysis by RT-qPCR and protein expression of Caspase-3, Collagen I, PCNA, and α-SMA were performed at 2, 4 and 8 weeks. RESULTS: The BUS was implanted successfully in all dogs (27/27) without surgery-related death. The ureter diameter and radiation injury score increased along with radiation accumulation (p < 0.05). Histopathologic analysis showed necrotic tissue and lateral fibrosis to different extents in the ureteral walls that gradually increased in all groups (p < 0.05); however, epithelial cell proliferation in groups A and B was lighter than that in the control group (p < 0.05). CONCLUSION: Placement of the newly designed 125I BUS was safe and feasible in dogs, and clinical studies are required to test its use in humans.
PURPOSE: To evaluate the safety and feasibility of a newly designed 125I brachytherapy ureteral stent (BUS) in normal dogs. METHODS: A BUS loaded with 10 125I seeds (Group A: 0.8 mCi, Group B: 0.4 mCi, Group C: 0 mCi) was designed and tested in 27 normal beagle dogs. Routine blood tests, gross observations, cumulative radiation doses, tissue reaction assessed by hematoxylin-eosin/Masson staining, mRNA analysis by RT-qPCR and protein expression of Caspase-3, Collagen I, PCNA, and α-SMA were performed at 2, 4 and 8 weeks. RESULTS: The BUS was implanted successfully in all dogs (27/27) without surgery-related death. The ureter diameter and radiation injury score increased along with radiation accumulation (p < 0.05). Histopathologic analysis showed necrotic tissue and lateral fibrosis to different extents in the ureteral walls that gradually increased in all groups (p < 0.05); however, epithelial cell proliferation in groups A and B was lighter than that in the control group (p < 0.05). CONCLUSION: Placement of the newly designed 125I BUS was safe and feasible in dogs, and clinical studies are required to test its use in humans.
Entities:
Keywords:
125Iodine; Animal study; Brachytherapy; Ureteral stent; Urinary system
Authors: Morgan Rouprêt; Marko Babjuk; Eva Compérat; Richard Zigeuner; Richard J Sylvester; Maximilian Burger; Nigel C Cowan; Andreas Böhle; Bas W G Van Rhijn; Eero Kaasinen; Joan Palou; Shahrokh F Shariat Journal: Eur Urol Date: 2015-07-16 Impact factor: 20.096
Authors: Marjolein Y V Homs; Wilhelmina M H Eijkenboom; Véronique L M A Coen; Jelle Haringsma; Mark van Blankenstein; Ernst J Kuipers; Peter D Siersema Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280